What Is a Phase 0 Clinical Trial?

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Phase 0 trials are exploratory first-in-human studies that use microdoses to gather early pharmacokinetic data before traditional Phase I dose-escalation trials begin.
• Clinical research professionals should understand that Phase 0 trials generate no therapeutic effect data and require specialized bioanalytical methods to measure drug levels.
• A key limitation is that Phase 0 results do not replace the need for full Phase I safety and tolerability studies, so career decisions should account for this narrow scope.

Understanding Phase 0 Clinical Trials

Phase 0 clinical trials represent a distinct category of early exploratory studies conducted before conventional Phase I trials. These studies are formally known as exploratory Investigational New Drug (IND) studies under regulatory frameworks that allow limited human exposure to a candidate drug. The primary purpose is to gather preliminary pharmacokinetic and pharmacodynamic information using subtherapeutic doses, often called microdoses, that are far below the anticipated therapeutic range.

The concept emerged from a need to make early drug development more efficient. Traditional drug development pathways require substantial investment before a compound reaches human testing. Phase 0 trials allow sponsors to obtain early human data on how a drug behaves in the body, including absorption, distribution, metabolism, and excretion, without committing to the full-scale safety and efficacy studies that Phase I trials require.

For clinical research professionals, understanding Phase 0 trials matters because these studies occupy a unique regulatory and operational space. They involve small numbers of participants, typically fewer than 20, and are designed to answer specific questions about drug behavior instead of safety or efficacy. This distinction affects how studies are designed, monitored, and documented.

The regulatory framework for Phase 0 trials was established to encourage innovation while maintaining participant protection. The approach allows sponsors to gather critical human data earlier in the development process, potentially avoiding costly late-stage failures. However, the data generated from Phase 0 studies are limited in scope and cannot replace the comprehensive safety assessment required in later phases.

Regulatory Framework and Definitions

The regulatory basis for Phase 0 trials comes from the U.S. Food and Drug Administration guidance on exploratory IND studies. This guidance describes a category of clinical studies that involve limited human exposure to a drug or biologic, with no therapeutic or diagnostic intent. The studies are designed to evaluate the mechanism of action, pharmacokinetics, or imaging properties of a compound.

The exploratory IND pathway is distinct from the traditional IND pathway. Traditional INDs are required for clinical studies that are intended to evaluate safety and efficacy for marketing approval. Exploratory INDs, by contrast, support studies that are not intended to establish safety or efficacy but rather to gather early information that informs whether further development is justified.

The FDA guidance identifies several types of exploratory studies, including microdose studies, studies of mechanism of action, and studies that evaluate the pharmacological effects of a drug. Microdose studies are the most common form of Phase 0 trials. A microdose is defined as less than one-hundredth of the pharmacologically active dose, with a maximum dose of 100 micrograms for small molecules and 30 nanomoles for protein products.

The regulatory requirements for exploratory INDs are less burdensome than those for traditional INDs. Sponsors are required to provide sufficient information to ensure participant safety, but the amount of preclinical data required is reduced. This reduction is possible because the doses used are so low that the risk of adverse effects is minimal.

The exploratory IND pathway is not a substitute for the traditional IND pathway. A drug that completes Phase 0 studies must still undergo the full development process, including Phase I safety studies, before it can be approved for marketing. The Phase 0 data are used to inform decisions about whether to proceed with further development and how to design subsequent studies.

Microdosing and Pharmacokinetic Assessment

Microdosing is the most common application of Phase 0 trial design. The approach involves administering a very small dose of a drug to a small number of participants to measure how the drug is absorbed, distributed, metabolized, and excreted. The data obtained from microdosing studies can be used to predict the pharmacokinetic behavior of the drug at therapeutic doses.

The scientific rationale for microdosing is that the pharmacokinetics of a drug are often dose-independent. This means that the way the body handles a drug at a microdose can be similar to the way it handles the drug at a therapeutic dose. However, this assumption does not hold for all drugs. Some drugs exhibit nonlinear pharmacokinetics, where the rate of metabolism or transport changes with dose. For these drugs, microdosing data may not accurately predict therapeutic-dose behavior.

Accelerator mass spectrometry is a key analytical tool used in microdosing studies. This technique can measure extremely low concentrations of a drug in biological samples, making it possible to track the drug through the body at microdose levels. The sensitivity of accelerator mass spectrometry allows researchers to obtain detailed pharmacokinetic data from a single microdose administration.

Positron emission tomography (PET) is another technique used in Phase 0 studies, particularly for drugs that target specific receptors or tissues. PET imaging can provide information about drug distribution and target engagement in the body. This information is valuable for understanding whether a drug reaches its intended site of action.

The choice of analytical method depends on the drug and the questions being asked. Accelerator mass spectrometry is used for measuring drug concentrations in blood and other biological samples. PET imaging is used for visualizing drug distribution in the body. Both techniques require specialized equipment and expertise, which adds to the operational complexity of Phase 0 trials.

Comparison with Phase I Trials

Phase 0 and Phase I trials serve different purposes in the drug development pathway. Phase I trials are the first studies to administer a drug to humans with the goal of evaluating safety, tolerability, and pharmacokinetics at escalating doses. Phase 0 trials are exploratory studies that gather preliminary data before Phase I begins.

The table below summarizes the key differences between Phase 0 and Phase I trials.

The distinction between Phase 0 and Phase I has practical implications for clinical research professionals. Phase 0 trials are shorter and involve fewer participants, which means they require less infrastructure and fewer resources. However, they also require specialized analytical methods and a clear understanding of the regulatory framework.

Phase I trials are more complex and require more extensive safety monitoring. They involve dose escalation, which means that participants receive increasing doses until a maximum tolerated dose is identified. This process requires careful monitoring for adverse effects and a clear protocol for stopping the trial if safety concerns arise.

The decision to conduct a Phase 0 trial before a Phase I trial depends on the drug and the development strategy. Some sponsors use Phase 0 trials to screen multiple drug candidates and select the most promising one for Phase I development. Others use Phase 0 trials to gather early pharmacokinetic data that can inform the design of the Phase I trial.

Career Pathways in Clinical Research

Clinical research professionals who are interested in Phase 0 trials can pursue several career pathways. The field includes roles in clinical trial coordination, clinical research management, regulatory affairs, and data management. Each role requires a different set of skills and educational background.

The U.S. Bureau of Labor Statistics provides information on the education and training requirements for clinical research roles. Medical scientists, for example, typically need a doctoral degree in a biological science or a related field. They may work in research and development, where they design and conduct studies that evaluate the safety and efficacy of drugs.

Clinical research coordinators are another important role in the clinical trial process. They are responsible for managing the day-to-day operations of a clinical trial, including participant recruitment, data collection, and regulatory compliance. The education and training requirements for this role vary, but many employers prefer candidates with a bachelor's degree in a health-related field and relevant experience.

The National Institutes of Health offers training and professional development programs for individuals interested in research careers. These programs provide opportunities for mentorship, skill development, and networking. The NIH also offers guidance on career paths in clinical research, including information on the skills and competencies needed for success.

The American Society for Microbiology provides career resources for individuals in the microbiology field, which is relevant to clinical research. These resources include information on professional roles, networking opportunities, and training programs. The ASM also offers guidance on career development for early-career professionals.

The Association of American Veterinary Medical Colleges provides career resources for individuals interested in veterinary medicine. While veterinary medicine is not directly related to Phase 0 trials, the skills and knowledge gained in veterinary research can be applied to clinical research, particularly in the area of animal models for drug development.

Skills and Competencies for Phase 0 Research

Working in Phase 0 trials requires a specific set of skills and competencies. These include a strong understanding of pharmacokinetics and pharmacodynamics, familiarity with regulatory requirements, and the ability to work with specialized analytical techniques.

Pharmacokinetics is the study of how the body processes a drug, including absorption, distribution, metabolism, and excretion. Pharmacodynamics is the study of how a drug affects the body. A solid understanding of both concepts is essential for designing and interpreting Phase 0 trials.

Regulatory knowledge is also important. Clinical research professionals must understand the requirements for exploratory INDs and the differences between exploratory and traditional INDs. They must also be familiar with the documentation and reporting requirements for clinical trials.

Analytical skills are necessary for working with the data generated from Phase 0 trials. This includes the ability to interpret pharmacokinetic data, understand the limitations of microdosing, and communicate findings to other members of the research team.

The O*NET OnLine database provides detailed information on the skills and knowledge required for clinical research occupations. For example, clinical research coordinators need skills in communication, critical thinking, and attention to detail. They also need knowledge of clinical research, regulatory requirements, and data management.

The National Science Foundation provides information on careers in scientific research, including the skills and education required for various roles. The NSF's careers page describes the work of scientists, program managers, and technical staff in a federal research organization. This information can be useful for individuals considering a career in clinical research.

Practical Implementation of Phase 0 Studies

Implementing a Phase 0 study requires careful planning and coordination. The process begins with the development of a study protocol that describes the objectives, design, and methods of the study. The protocol must be approved by an institutional review board (IRB) before the study can begin.

The study protocol for a Phase 0 trial is typically shorter and less complex than a protocol for a Phase I trial. It focuses on the pharmacokinetic and pharmacodynamic questions that the study is designed to answer. The protocol must also include a detailed description of the microdose to be administered and the analytical methods to be used.

Participant recruitment for Phase 0 trials is often easier than for later-phase trials because the risk to participants is minimal. However, the participants must still meet the inclusion and exclusion criteria specified in the protocol. These criteria are designed to ensure that the participants are healthy and that the study results are not confounded by other factors.

The study team for a Phase 0 trial typically includes a principal investigator, a clinical research coordinator, a pharmacist, and a laboratory technician. The principal investigator is responsible for the overall conduct of the study. The clinical research coordinator manages the day-to-day operations. The pharmacist prepares the study drug, and the laboratory technician performs the analytical measurements.

Data collection and management are critical components of a Phase 0 trial. The data collected include pharmacokinetic parameters, such as the maximum concentration of the drug in the blood and the time to reach that concentration. The data must be recorded accurately and stored securely to ensure the integrity of the study.

Records and Measurements in Phase 0 Trials

Accurate records and measurements are essential for the success of a Phase 0 trial. The data collected in a Phase 0 trial are used to make decisions about whether to proceed with further development of the drug. Poor data quality can lead to incorrect conclusions and wasted resources.

The primary measurements in a Phase 0 trial are pharmacokinetic parameters. These include the maximum concentration of the drug in the blood, the time to reach the maximum concentration, the area under the concentration-time curve, and the half-life of the drug. These parameters are calculated from the concentration of the drug in blood samples collected at various times after administration.

The analytical methods used to measure drug concentrations must be validated before the study begins. Validation ensures that the method is accurate, precise, and sensitive enough to detect the drug at the concentrations expected in the study. The validation process involves testing the method with known concentrations of the drug and documenting the results.

The records for a Phase 0 trial include the study protocol, the informed consent forms, the case report forms, and the laboratory reports. These records must be maintained in accordance with regulatory requirements and must be available for inspection by regulatory authorities.

The data from a Phase 0 trial are typically analyzed using non-compartmental methods. These methods calculate the pharmacokinetic parameters from the concentration-time data without assuming a specific compartmental model. The results are then compared with the results from preclinical studies to determine whether the drug behaves in humans as expected.

Common Failure Patterns in Phase 0 Trials

Phase 0 trials can fail for several reasons. Understanding these failure patterns can help clinical research professionals design better studies and avoid common pitfalls.

One common failure pattern is the use of a microdose that is too low to produce measurable drug concentrations. If the analytical method is not sensitive enough to detect the drug at the microdose level, the study will not generate useful data. This can be avoided by validating the analytical method before the study begins and by selecting a microdose that is high enough to be measured.

Another failure pattern is the assumption that the pharmacokinetics of the drug are linear. If the drug exhibits nonlinear pharmacokinetics, the data from the microdose study may not predict the behavior of the drug at therapeutic doses. This can lead to incorrect decisions about the drug's development. The risk of nonlinear pharmacokinetics can be assessed by reviewing the preclinical data and by considering the drug's mechanism of action.

A third failure pattern is the lack of a clear scientific question. Phase 0 trials are designed to answer specific questions about the drug's behavior. If the study is not designed to answer a clear question, the results may be difficult to interpret and may not support a decision about the drug's development.

A fourth failure pattern is the failure to include the appropriate participants. Phase 0 trials are typically conducted in healthy volunteers, but some drugs may require participants with a specific condition. If the participants do not represent the population that will receive the drug, the results may not be generalizable.

Welfare and Safety Context

The safety of participants is a primary concern in Phase 0 trials. Although the doses used are subtherapeutic, the studies are not without risk. The risk is minimized by the low dose, but it is not eliminated.

The FDA guidance on exploratory INDs requires that the studies be conducted in accordance with good clinical practice. This includes the requirement for an institutional review board to review and approve the study protocol, the requirement for informed consent from participants, and the requirement for monitoring of the study.

The risk of adverse effects in a Phase 0 trial is low, but it is not zero. The participants must be monitored for adverse effects, and the study must be stopped if a serious adverse effect occurs. The study protocol must include a plan for the management of adverse effects and for the reporting of serious adverse effects to the regulatory authorities.

The welfare of participants is also a consideration in the design of the study. The study should be designed to minimize the burden on participants, including the number of blood samples and the duration of the study. The participants should be compensated for their time and inconvenience, but the compensation should not be so high that it encourages participation in a study that is not in the participant's best interest.

Limitations of Phase 0 Trials

Phase 0 trials have several limitations that must be considered when interpreting the results. The most important limitation is that the data from a Phase 0 trial do not provide information about the safety or efficacy of the drug at therapeutic doses. The microdose is too low to produce a therapeutic effect, and the study is not designed to detect adverse effects.

The pharmacokinetic data from a Phase 0 trial may not predict the pharmacokinetics of the drug at therapeutic doses. This is particularly true for drugs with nonlinear pharmacokinetics, where the behavior of the drug changes with dose. The data from a Phase 0 trial should be used with caution when making decisions about the drug's development.

The results of a Phase 0 trial are also limited by the small number of participants. The study is typically conducted in fewer than 20 participants, which means that the results may not be representative of the broader population. The results may also be affected by the variability between participants.

The Phase 0 trial is not a substitute for a Phase I trial. The Phase I trial is required to assess the safety and tolerability of the drug at therapeutic doses. The Phase 0 trial can inform the design of the Phase I trial, but it cannot replace it.

Professional Escalation Criteria

Clinical research professionals should know when to escalate a concern in a Phase 0 trial. Escalation is the process of reporting a concern to a higher level of authority, such as the principal investigator or the regulatory body.

A concern should be escalated if a participant experiences a serious adverse event. The serious adverse event must be reported to the principal investigator and the institutional review board within a specified time frame. The regulatory body must also be notified if the event is unexpected and related to the drug.

A concern should also be escalated if the data from the study are not consistent with the expected results. For example, if the drug is not detected in the blood samples, the analytical method may be faulty, or the drug may not be absorbed. The concern should be reported to the principal investigator, who can decide whether to continue the study or to modify the protocol.

A concern should be escalated if the study is not being conducted in accordance with the protocol or with regulatory requirements. This includes issues with the informed consent process, the management of the study, or the reporting of the data. The concern should be reported to the principal investigator and the institutional review board.

The escalation process is important for the integrity of the study and the safety of the participants. It is the responsibility of every member of the study team to report concerns in a timely manner.

Frequently Asked Questions

What is the difference between a Phase 0 and a Phase I clinical trial?

A Phase 0 trial is an exploratory study that uses a microdose to gather early pharmacokinetic data. A Phase I trial is the first study to evaluate the safety and tolerability of a drug at escalating doses. Phase 0 trials are shorter and involve fewer participants than Phase I trials.

What is a microdose in a Phase 0 trial?

A microdose is a dose that is less than one-hundredth of the pharmacologically active dose, with a maximum of 100 micrograms for small molecules. The microdose is too low to produce a therapeutic effect but high enough to measure the drug's behavior in the body.

What are the regulatory requirements for a Phase 0 trial?

The regulatory requirements for a Phase 0 trial are described in the FDA guidance on exploratory IND studies. The requirements are less burdensome than those for a traditional IND, but the study must still be conducted in accordance with good clinical practice.

What are the career opportunities in Phase 0 research?

Career opportunities in Phase 0 research include roles as clinical research coordinators, clinical research associates, and regulatory affairs specialists. These roles require a background in the life sciences and an understanding of clinical research and regulatory requirements.

What are the limitations of Phase 0 trials?

The limitations of Phase 0 trials include the lack of safety and efficacy data, the potential for nonlinear pharmacokinetics, and the small number of participants. The data from a Phase 0 trial cannot be used to predict the safety or efficacy of a drug at therapeutic doses.

How long does a Phase 0 trial take?

A Phase 0 trial is typically shorter than a Phase I trial. The study may involve a single dose of the drug and a short follow-up period. The duration of the study depends on the design and the analytical methods used.

What is the role of the institutional review board in a Phase 0 trial?

The institutional review board reviews the study protocol to ensure that the study is ethical and that the participants are protected. The board must approve the study before it can begin, and it must be informed of any serious adverse events.

What is the role of the clinical research coordinator in a Phase 0 trial?

The clinical research coordinator manages the day-to-day operations of the study, including participant recruitment, data collection, and regulatory compliance. The coordinator works with the principal investigator to ensure that the study is conducted in accordance with the protocol.

Using the Evidence

Related Articles

• Clinical Research Coordinator vs. Clinical Trial Coordinator: What's the Difference?
• Worldwide Clinical Trials: How Global Studies Are Conducted
• Randomized Clinical Trials: Design, Conduct, and Analysis
• Double-Blind Studies: Design and Interpretation
• Clinical Trial Phases Explained: From Phase 0 to Phase 4

References and Further Reading

• Occupational Outlook Handbook. U.S. Bureau of Labor Statistics.
• O*NET OnLine. U.S. Department of Labor.
• Office of Intramural Training and Education. National Institutes of Health.
• Careers at NSF. U.S. National Science Foundation.
• Career Services. American Society for Microbiology.
• AAVMC Career Resources. Association of American Veterinary Medical Colleges.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.